Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Thea H. Wiken, Marte Lie Høivik, L. Buer, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 58, Iss. 8, pp. 863-873
Open Access | Times Cited: 19

Showing 19 citing articles:

Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease
Carmen Amor Costa, Cristina Suárez Ferrer, Laura García Ramírez, et al.
Gastroenterología y Hepatología (English Edition) (2025), pp. 502201-502201
Closed Access
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Davide Giuseppe Ribaldone, L Parisio, Angela Variola, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 77-82
Open Access | Times Cited: 11
Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies
Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 171-189
Closed Access | Times Cited: 3
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
William J. Sandborn, Jingjing Chen, Krisztina Kisfalvi, et al.
Crohn s & Colitis 360 (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 5
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
Špela Pintar, Jurij Hanžel, David Drobne, et al.
Medicina (2024) Vol. 60, Iss. 2, pp. 296-296
Open Access | Times Cited: 1
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
N. Lamichhane, Nikolaos Melas, Viktoria Bergqvist, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 6, pp. 2175-2183
Open Access | Times Cited: 1
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
Ferdinando D’Amico, Luca Massimino, Giulia Palmieri, et al.
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 11
Open Access | Times Cited: 1
Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study
Mariabeatrice Principi, Irene Brescia, Elisa Stasi, et al.
Digestive Diseases and Sciences (2024)
Closed Access | Times Cited: 1
Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses
Jenniina Harno-Tasihin, Laura Siregar, Mikko Paajanen, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 59, Iss. 3, pp. 280-287
Closed Access | Times Cited: 4
Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort
Alica Kubesch, N. A. Kruse, Florian Jungheim, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 24, pp. 7657-7657
Open Access | Times Cited: 4
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Thea H. Wiken, Marte Lie Høivik, Karoline Anisdahl, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Take vedolizumab home: transition from intravenous to subcutaneous treatment
Kaituo Huang, Lingya Yao, Jing Liu, et al.
Therapeutic Advances in Chronic Disease (2024) Vol. 15
Open Access | Times Cited: 1
Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary
Péter Bacsúr, Ákos Iliás, Tamás Resál, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 2, pp. 262-263
Open Access | Times Cited: 2
VALORACIÓN DE LA TRANSICIÓN DE VEDOLIZUMAB INTRAVENOSO A SUBCUTÁNEO EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL
Carmen Amor Costa, Cristina Suárez Ferrer, Laura García Ramírez, et al.
Gastroenterología y Hepatología (2024), pp. 502201-502201
Closed Access
Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease
Sara Kolehmainen, Jaakko Rautakorpi, Eliisa Löyttyniemi, et al.
European Journal of Gastroenterology & Hepatology (2024) Vol. 36, Iss. 10, pp. 1193-1201
Closed Access
Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases
Alexander T. Elford, Rishni Heldt, Shahed Kamal, et al.
European Journal of Gastroenterology & Hepatology (2024)
Closed Access
Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases
Péter Bacsúr, Tamás Resál, Patrícia Sarlós, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis
Wei Chen, Yuhang Liu, Yuelun Zhang, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access
Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents
Omar I. Saadah, Turki AlAmeel, Ahmed Al Sarkhy, et al.
Saudi Journal of Gastroenterology (2024)
Open Access
Page 1

Scroll to top